MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on October 17, 2006; DOI: 10.1124/mol.106.030700


This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.106.030700v1
71/1/112    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Awobuluyi, M.
Right arrow Articles by Zhang, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Awobuluyi, M.
Right arrow Articles by Zhang, D.


Received for publication September 11, 2006.
Revised October 13, 2006.
Accepted for publication October 17, 2006.

Subunit-specific Roles of Gycine-Binding Domains in Activation of NR1/NR3 "NMDA" Receptors

Marc Awobuluyi 1, Jin Yang 1, Yuzhen Ye 1, Jon E Chatterton 1, Adam Godzik 1, Stuart A Lipton 1, Dongxian Zhang 1*

1 Burnham Institute for Medical Research

* Address correspondence to: E-mail: dzhang{at}burnham.org

Abstract

NMDA receptors (NMDARs) comprised of NR1 and NR3 subunits differ from other NMDAR subtypes in that they require glycine alone for activation. However, little else is known about the activation mechanism of these receptors. Using NMDAR glycine-site agonists/antagonists in conjunction with functional mutagenesis of the NR1 and NR3 ligand-binding cores, we demonstrate quite surprisingly that agonist binding to NR3 alone is sufficient to activate a significant component of NR1/NR3 receptor currents. Thus, the apo conformation of NR1 in NR1/NR3 receptors is permissive for receptor activation. Agonist-bound NR1 may also contribute to peak NR1/NR3 receptor currents, but specifically enables significant NR1/NR3 receptor current decay under the conditions studied here, presumably via a slow component of desensitization. Ligand studies of NR1/NR3 receptors also suggest differential agonist selectivity between NR3 and NR1, as some high affinity NR1 agonists activate NR1/NR3 receptors only poorly, whereas other NR1 agonists are as potent as glycine. Furthermore, liganded NR3 subunits appear necessary for effective engagement of NR1 in NR1/NR3 receptor activation, suggesting significant interactivity between the two subunits. NR3 subunits thus induce plasticity in NR1 with respect to subunit assembly and ligand binding/channel coupling that is unique amongst ligand-gated ion channel subunits.


Key words: Glutamate, Structure-activity relationships and modeling, Func. analysis receptor/ion channel mutants, Mutagenesis/Chimeric approaches


This article has been cited by other articles:


Home page
Proc. Natl. Acad. Sci. USAHome page
C. Madry, H. Betz, J. R. P. Geiger, and B. Laube
Supralinear potentiation of NR1/NR3A excitatory glycine receptors by Zn2+ and NR1 antagonist
PNAS, August 26, 2008; 105(34): 12563 - 12568.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
P. T. Atlason, M. L. Garside, E. Meddows, P. Whiting, and R. A. J. McIlhinney
N-Methyl-D-aspartate (NMDA) Receptor Subunit NR1 Forms the Substrate for Oligomeric Assembly of the NMDA Receptor
J. Biol. Chem., August 31, 2007; 282(35): 25299 - 25307.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
C. T. Smothers and J. J. Woodward
Pharmacological Characterization of Glycine-Activated Currents in HEK 293 Cells Expressing N-Methyl-D-aspartate NR1 and NR3 Subunits
J. Pharmacol. Exp. Ther., August 1, 2007; 322(2): 739 - 748.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2006 by the American Society for Pharmacology and Experimental Therapeutics